Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation TCT Abstracts Posters 2018

Comparison of clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation

Presenter: Hyungdon Kook

September 25, 2018

Presentation TCT 2018

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

Presenter: Dominick J. Angiolillo, Neal S. Kleiman, Ajay J. Kirtane

September 24, 2018

Presentation TCT 2018

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Presenter: John A. Bittl, C. Michael Gibson, Matthew J. Price

September 23, 2018

Presentation TCT 2018

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

Presenter: John A. Bittl, C. Michael Gibson, Giuseppe Tarantini

September 23, 2018

Presentation TCT 2018

LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy

Presenter: Mitchell W. Krucoff

September 22, 2018

Presentation TCT 2018

TCT-1: Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

Presenter: Steven R. Bailey, Patrick W. Serruys, Sorin J. Brener

September 22, 2018

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

Presentation JIM 2018

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

Presenter: Roxana Mehran

February 23, 2018

Advertisement

Comparison of clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy

TCT-1: Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content